Shares in IXICO PLC (LSE:IXI, OTC:PHYOF) rose 9% after the neuro-imaging specialist confirmed its involvement in the first FDA-approved blood test for Alzheimer’s disease diagnosis.
The UK-listed company provided imaging analysis for Fujirebio Diagnostics’ Lumipulse test, which received US regulatory clearance in May.
The test detects key proteins linked to amyloid build-up, a hallmark of Alzheimer’s, through a simple blood sample.
It offers a less invasive and more scalable alternative to brain scans or spinal taps and is intended for use in specialist clinics for patients aged 50 and over with memory issues.
IXICO applied its artificial intelligence tools to analyse data from the Bio-Hermes-001 study, a major international trial backed by the Global Alzheimer’s Platform Foundation.
Its work helped standardise brain scan readings used as the gold-standard comparator.
The test is expected to accelerate early diagnosis and improve screening efficiency in clinical practice and drug development.
Up 35% in the last month, the shares were trading 1p higher at 12.5p mid-morning.